000291408 001__ 291408
000291408 005__ 20241030150257.0
000291408 0247_ $$2doi$$a10.3390/microorganisms12061205
000291408 0247_ $$2pmid$$apmid:38930587
000291408 0247_ $$2pmc$$apmc:PMC11205804
000291408 0247_ $$2altmetric$$aaltmetric:164830076
000291408 037__ $$aDKFZ-2024-01382
000291408 041__ $$aEnglish
000291408 082__ $$a570
000291408 1001_ $$aMakioka, Daiki$$b0
000291408 245__ $$aQuantification of HPV16 E7 Oncoproteins in Urine Specimens from Women with Cervical Intraepithelial Neoplasia.
000291408 260__ $$aBasel$$bMDPI$$c2024
000291408 3367_ $$2DRIVER$$aarticle
000291408 3367_ $$2DataCite$$aOutput Types/Journal article
000291408 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1719835778_5816
000291408 3367_ $$2BibTeX$$aARTICLE
000291408 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000291408 3367_ $$00$$2EndNote$$aJournal Article
000291408 520__ $$aWe present the validity of using an ultrasensitive enzyme-linked immunosorbent assay (ELISA) for quantifying high-risk human papillomavirus (HPV) 16 E7 oncoproteins in urine specimens as a noninvasive method of analyzing the oncogenic activity of HPV. Some reports claim that the oncogenic activity of HPV is a more relevant clinical indicator than the presence of HPV DNA for estimating malignant potential. In the present study, urine containing HPV16 and related types were selected by uniplex E6/E7 polymerase chain reaction and classified according to the pathologic diagnosis of cervical intraepithelial neoplasia (CIN) in cervical biopsy specimens. Our ultrasensitive ELISA was able to detect attomole levels of HPV16 E7 oncoproteins, and it detected HPV16-positive SiHa cells at >500 cells/mL without detecting HPV18-positive cells. Our ELISA results showed E7 oncoproteins in 80% (4/5) of urine specimens from women with HPV16-positive CIN1, 71% (5/7) of urine specimens from CIN2 patients, and 38% (3/8) of urine specimens from CIN3 patients. Some urine specimens with undetectable E7 oncoproteins were thought to be negative for live HPV 16-positive cells or in an inactivated state of infection. These results provide the basis for assessing oncogenic activity by quantifying E7 oncoproteins in patient urine.
000291408 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000291408 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000291408 650_7 $$2Other$$aE7 oncoprotein
000291408 650_7 $$2Other$$ahuman papillomavirus
000291408 650_7 $$2Other$$anoninvasive diagnosis
000291408 650_7 $$2Other$$aultrasensitive ELISA
000291408 650_7 $$2Other$$auniplex E6/E7 PCR
000291408 650_7 $$2Other$$aurine
000291408 7001_ $$aInada, Mikio$$b1
000291408 7001_ $$aAwano, Masayuki$$b2
000291408 7001_ $$aSaito, Ema$$b3
000291408 7001_ $$aShinoda, Takuya$$b4
000291408 7001_ $$aAbe, Satoko$$b5
000291408 7001_ $$aYoshimura, Teruki$$b6
000291408 7001_ $$0P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579$$aMüller, Martin$$b7$$udkfz
000291408 7001_ $$00000-0002-8480-844X$$aSasagawa, Toshiyuki$$b8
000291408 7001_ $$00000-0002-1877-6566$$aIto, Etsuro$$b9
000291408 773__ $$0PERI:(DE-600)2720891-6$$a10.3390/microorganisms12061205$$gVol. 12, no. 6, p. 1205 -$$n6$$p1205$$tMicroorganisms$$v12$$x2076-2607$$y2024
000291408 8564_ $$uhttps://inrepo02.dkfz.de/record/291408/files/microorganisms-12-01205.pdf
000291408 8564_ $$uhttps://inrepo02.dkfz.de/record/291408/files/microorganisms-12-01205.pdf?subformat=pdfa$$xpdfa
000291408 8564_ $$uhttps://inrepo02.dkfz.de/record/291408/files/cancers-16-00718-v2.pdf
000291408 8564_ $$uhttps://inrepo02.dkfz.de/record/291408/files/cancers-16-00718-v2.pdf?subformat=pdfa$$xpdfa
000291408 909CO $$ooai:inrepo02.dkfz.de:291408$$pVDB
000291408 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000291408 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000291408 9141_ $$y2024
000291408 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMICROORGANISMS : 2022$$d2023-08-26
000291408 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000291408 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000291408 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-26
000291408 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:01:16Z
000291408 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:01:16Z
000291408 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:01:16Z
000291408 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-04-12T15:01:16Z
000291408 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000291408 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-26
000291408 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-26
000291408 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-26
000291408 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-26
000291408 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-26
000291408 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-26
000291408 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-26
000291408 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-26
000291408 9201_ $$0I:(DE-He78)D335-20160331$$kD335$$lTumorvirus-spez. Vakzinierungsstrategie$$x0
000291408 980__ $$ajournal
000291408 980__ $$aVDB
000291408 980__ $$aI:(DE-He78)D335-20160331
000291408 980__ $$aUNRESTRICTED